Loading... Please wait...
About Us
Contact Us
Privacy Policy
Sign in
or
Create an account
My Account
View Cart
Checkout
Search
Home
Report Subject
Market Access
Browse by
Biosimilar Index
Dossier
FirstView
FirstView NPS+
FirstWord Pharma
Therapy Trends
Therapy Trends Updates
Latest Reports
Therapy Area Reports
Report Subject
Emerging Markets
Generics/Biosimilars
Market Access
Medical Affairs
Pharma Marketing
Pharma Sales
Technology/Digital Health
Orphan Drugs
Sort by:
Featured Items
Newest Items
Bestselling
Alphabetical: A to Z
Alphabetical: Z to A
Next »
Pages:
1
2
3
4
5
6
Learn More
Benchmarking Key Account Management Capabilities (2019)
What factors determine a Key Account Manager (KAM) team's size and structure? At what stage in a product's lifecycle are KAMs assigned and how many brands should a typical KAM support? What personal attributes and...
Compare
Learn More
The Future of Key Account Management in Pharma
Are you ready for fundamental disruption to key account management practice? While the Key Account Management (KAM) role will continue to prioritise the development of long-term, sustainable partnerships between...
Compare
Learn More
Real-World Data Capabilities: Benchmarking Pharma Companies (2019)
Are you fully and efficiently exploiting real-world data across your business? The impact of real-world data (RWD) is growing but few companies are fully exploiting its potential across all clinical and commercial areas...
Compare
Learn More
KAM Metrics: Measuring Success (2019)
Secure a successful future for your KAM teams by proving their true value KAM teams are still evolving but they're also concerned about their future. They need appropriate measures to demonstrate their true value...
Compare
Learn More
Indication-level Pricing: Payer Insights
Can pharma persuade payers of the benefits of indication-level pricing? Advocates argue that indication-level pricing can bring new products on stream and results in wider patient access to new therapies. That's a good...
Compare
Learn More
Real World Data and Evidence: Payer Insights
Payers have great expectations for real world data. Is pharma meeting them? It's sink or swim time. Advancements in drug data collection methodologies and deeper understanding of what can be achieved has finally opened...
Compare
Learn More
Review of Influence: The Institute for Clinical and Economic Review (ICER)
As the Institute for Clinical and Economic Review's (ICER) influence on payer behaviour and health policy grows, how should pharma respond? The ICER's novel and inclusive work on the value of drugs, using its own value...
Compare
Learn More
HTA in Europe: Key Success Factors for Positive HTA Recommendations
Is there a magic formula for achieving HTA approvals in Europe? Securing a HTA approval in Europe makes sound commercial sense but it's proving easier said than done. Negative or restrictive HTA recommendations are on...
Compare
Learn More
Paying for Digital Health: Payer Insights
Payers love digital technologies that reduce health costs and deliver patient benefit–but who should pick up the tab? Digital technology is revolutionising healthcare from advanced electronic medical records and...
Compare
Learn More
Pricing and Reimbursement in Neurology
When first line treatments for neurological diseases such as Parkinson's Disease (PD) and Multiple Sclerosis (MS) have been around for years, it's understandable that when something new is approved, people want to try it...
Compare
Learn More
Pricing and Reimbursement in Oncology: Payer views
As payer and stakeholder anger mounts, when will the oncology drug price bubble burst? Global cancer drug prices have increased by 10% every year between 1995 and 2013. That level of price inflation is not sustainable...
Compare
Learn More
Value-Added Services in Oncology: What motivates payers?
Are your value-added services (VAS) in oncology meeting the needs of payers as well as patients and physicians? Payers are increasingly taking interest in beyond-the-pill services that improve patient adherence,...
Compare
Learn More
The Importance of Real World Evidence in Orphan Drugs
Proof of value is an imperative for orphan drug manufacturers: it's the only route to improving patient access and overcoming unmet therapeutic needs for rare conditions. Progress has been made with real world data (RWD)...
Compare
Learn More
Market Access Team Structure and Function: Industry Survey 2017
This report gives a unique insight into how US and European market access teams are organised and how they are focusing their time on a day-to-day basis. Market Access Team Structure and Function: Industry Survey 2017...
Compare
Learn More
Innovative drugs: Mapping the pricing, reimbursement and HTA landscape
Widespread patient access to innovative new products is being frustrated in non-US markets by Health Technology Assessments (HTA). Between January 2016 and June 2017, 58 innovative medicines were approved and launched in...
Compare
Learn More
Value-Added Services in Cardiometabolic Diseases
Pharma's Value-Added Services (VAS) in cardiometabolic disease are not universally appreciated – why? Too often, useful programmes to monitor, educate and support patients are quietly dropped post launch. No wonder...
Compare
Next »
Pages:
1
2
3
4
5
6
About Us
Contact Us
Privacy Policy
customer.service@firstwordpharma.com
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved